Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

CDK9-IN-33

Copy Product Info
😃Good
Catalog No. T210374

CDK9-IN-33 (compound C35) is a potent, selective, and orally bioavailable CDK9 inhibitor with IC50 values of 17.44 nM for CDK9, 160 nM for CDK7, 316.30 nM for CDK2, 1771.00 nM for CDK4, and >10000 nM for CDK6. This compound induces apoptosis (cell apoptosis) and reduces the protein expression of RPB1 CTD Ser2, RPB1, and MCL1, exhibiting antitumor activity.

CDK9-IN-33

CDK9-IN-33

Copy Product Info
😃Good
Catalog No. T210374
CDK9-IN-33 (compound C35) is a potent, selective, and orally bioavailable CDK9 inhibitor with IC50 values of 17.44 nM for CDK9, 160 nM for CDK7, 316.30 nM for CDK2, 1771.00 nM for CDK4, and >10000 nM for CDK6. This compound induces apoptosis (cell apoptosis) and reduces the protein expression of RPB1 CTD Ser2, RPB1, and MCL1, exhibiting antitumor activity.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
10 mgInquiryInquiryInquiry
50 mgInquiryInquiryInquiry
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
CDK9-IN-33 (compound C35) is a potent, selective, and orally bioavailable CDK9 inhibitor with IC50 values of 17.44 nM for CDK9, 160 nM for CDK7, 316.30 nM for CDK2, 1771.00 nM for CDK4, and >10000 nM for CDK6. This compound induces apoptosis (cell apoptosis) and reduces the protein expression of RPB1 CTD Ser2, RPB1, and MCL1, exhibiting antitumor activity.
Targets&IC50
CDK2:316.30 nM, CDK7:160 nM, CDK4:1771.00 nM, CDK6:>10000 nM, CDK9:17.44 nM
In vitro
CDK9-IN-33 (compound C35) at concentrations of 0, 0.01, 0.1, and 1 µM for 24 hours reduces the protein expression of RPB1 CTD Ser2, RPB1, and MCL1 while enhancing the expression of cleaved PARP. Additionally, CDK9-IN-33 at the same concentrations lowers MCL1 gene mRNA levels. Over 72 hours, CDK9-IN-33 induces apoptosis in a dose-dependent manner.
In vivo
CDK9-IN-33 (10 mg/kg; p.o.; daily for 10 days) demonstrates antitumor activity in mice.
Chemical Properties
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy CDK9-IN-33 | purchase CDK9-IN-33 | CDK9-IN-33 cost | order CDK9-IN-33 | CDK9-IN-33 in vivo | CDK9-IN-33 in vitro